Vivo Bio Tech Ltd Financials
Company Logo

Vivo Bio Tech Ltd Financial Statement

Vivo Bio Tech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2024
Revenue11.56
Operating Expense6.22
Net Profit0.70
Net Profit Margin6.06
Earning Per Share0.47
EBIDTA5.38
Effective Tax Rate13.67

Vivo Bio Tech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Total Revenue Annual51.62
Operating Expenses Annual30.14
Operating Profit Annual21.52
Interest Annual7.65
Depreciation9.27
Net Profit Annual2.63
Tax Annual1.97

Vivo Bio Tech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Cash Flow at the Beginning1.47
Cash Flow from Operations14.73
Cash Flow from Investing-4
Cash Flow from Financing-11.20
Cash Flow at the End0.99

Vivo Bio Tech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
PBDIT Margin (%)42.35
PBIT Margin (%)24.39
PBT Margin (%)21.33
Net PROFIT Margin (%)5.09
Return On Networth / Equity (%)5.31
Return On Networth /Employed (%)11.16
Return On Assets (%)2.34
Total Debt / Equity (X)1.27
Asset Turnover Ratio (%)0.46

Vivo Bio Tech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Fixed Assets Annual85.51
Total Current Assets Annual32.88
Non Current Assets Annual87.92
Total Shareholders Funds Annual51.87
Total Assets Annual120.81

Vivo Bio Tech Ltd Earning Calls

EPS (INR)

Expected

0.50

Reported

0.50

Surprise

0.00%

Dec 2023

EPS beaten by 0.00%

Sep 2023

EPS beaten by 0.00%

Jun 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Jul 27, 2024, Vivo Bio Tech Ltd has a market capitalization of 63.89 Cr. Value Research classifies it as a Micro-Cap company.
No, Vivo Bio Tech Ltd is not debt-free with a debt-to-equity ratio of 1.30.
In FY 2023 , Vivo Bio Tech Ltd recorded a total revenue of approximately 44.88 Cr marking a significant milestone in the company's financial performance.
Vivo Bio Tech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and -0.1% annually, respectively..
Vivo Bio Tech Ltd's current PE ratio is 25.35.
Vivo Bio Tech Ltd's ROCE averaged 9.3% from the FY ending March 2022 to 2024, with a median of 9.4%. It peaked at 10.9% in March 2023, reflecting strong capital efficiency over the period..
Vivo Bio Tech Ltd's latest EBIT is Rs. 11.83 Cr, surpassing the average EBIT of Rs. 10.85 Cr over the 5 years..